Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05611203
Other study ID # H-22022937
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 10, 2022
Est. completion date March 2, 2023

Study information

Verified date January 2023
Source Rigshospitalet, Denmark
Contact Tobias Todsen, MD, PhD
Phone +45 35466008
Email tobias.todsen@regionh.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Citizens who undergo testing for COVID-19 at one of two Testcenters in Copenhagen Captial Region will be invited to participate in the study. The participants will be randomized to either an oropharyngeal swap including the palatine tonsils OR an oropharyngeal swap without the palatine tonsils for SARS-CoV-2 testing. The swabs will be sent to the clinical microbiology laboratory for SARS-CoV-2 detection using RT-PCR. The diagnostic accuracy and SARS-CoV-2 viral load will be compared. The participants will be asked to complete a questionnaire regarding their symptoms.


Description:

We will include citizens referred for outpatient testing for COVID-19 who will be offered to participante in the study on a volunteer basis. Participants are all volunteers, who are attending the test facilities to obtain a PCR test. Participants are required to provide oral and written informed consent to participate before entering the study. The inclusion criterion is 18 years or more of age. Exclusion criteria are neck breathers (tracheostomy/laryngectomy patients). The participants will be randomized to either an oropharyngeal swap including the palatine tonsils OR an oropharyngeal swap without the palatine tonsils for SARS-CoV-2 testing. The swabs will be sent to the clinical microbiology laboratory for SARS-CoV-2 detection using RT-PCR as usual. The diagnostic accuracy and SARS-CoV-2 viral load will be compared using independent t-test. The participants will be asked to complete a questionnaire regarding their symptoms and the number of sick days. All data will be documented on-site in a secure web database (REDCap). The primary outcome will be reported as: • SARS-CoV-2 RNA by RT-PCR test result (positive, negative, inconclusive) The secondary outcome will be reported as: - SARS-CoV-2 RT-PCR cycle threshold (Ct) value - Test discomfort on a 11-point NRS-scale - Development of COVID-19 disease after testing - SARS-CoV-2 detection rate for each healthcare worker - Mallampati Score of participants being tested


Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date March 2, 2023
Est. primary completion date January 30, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - citizens referred for outpatient testing for COVID-19 in Valby and Hillerød COVID-19 TestCenter. Exclusion Criteria: - Age under 18 years - neck breathers (tracheostomy/laryngectomy patients)

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
An Oropharyngeal swab
An Oropharyngeal swab performed for diagnostic purposes

Locations

Country Name City State
Denmark Hillerød Covid-19 Testcenter Copenhagen Hillerød
Denmark Valby Copenhagen

Sponsors (1)

Lead Sponsor Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary RT-PCR results The detection rate of SARS-CoV-2 RNA Day 1
Secondary Sycle threshold (Ct) SARS-CoV-2 RT-PCR cycle threshold (Ct) values Day 1
Secondary Inconclusive tests Number of inconclusive RT-PCR tests results Day 1
Secondary Test discomfort Self reported on a 11-point NRS-scale from 0 - 10 (with 10 being the worst imaginable discomfort) Day 1
Secondary Development of COVID-19 disease after testing Online questionare about symptoms send by email 1 month
Secondary Test accuracy between healthcare workers SARS-CoV-2 detection rate for each healthcare worker Day 1
Secondary Participants oropharynx anatomy Mallampati Score of participants Day 1
See also
  Status Clinical Trial Phase
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT04578210 - Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia Phase 1/Phase 2
Completed NCT05065827 - Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
Completed NCT04720794 - A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusion N/A
Enrolling by invitation NCT04659486 - Adolescents With COVID-19/MIS-C at HCFMUSP N/A
Completed NCT04598620 - Non-invasive Prognostication of COVID-19 Patients by Use of Biomarkers in Exhaled Breath Condensate
Completed NCT05517941 - Effect of Active Cycle Breathing Technique Along With Incentive Spirometer on COVID19 Patient N/A
Recruiting NCT04480333 - Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831 Phase 1
Recruiting NCT04565782 - Corona Virus Infection Among Liver Transplant Recipients
Active, not recruiting NCT04558476 - Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation Phase 2
Completed NCT04526769 - Detecting SARS-CoV-2 in Tears
Completed NCT05639998 - BBV152/BBV154 Heterologus Prime-Boost Study Phase 2
Withdrawn NCT04386447 - Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19 Phase 2
Completed NCT04523246 - Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents Early Phase 1
Completed NCT05736926 - Anal Fissure Among Survivors of COVID-19 Virus Infection.
Recruiting NCT04583566 - Differential Expression of Cytokines, Transcriptome and miRNA in Coronavirus Disease 2019 (COVID-19) Egyptian's Patients
Completed NCT04643678 - Anakinra in the Management of COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04579588 - Understanding Immunity to the Flu Vaccine in COVID-19 Patients
Terminated NCT03331445 - Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections Phase 2
Recruiting NCT04573348 - T Cells Response to SARS COV 2 Peptides